Evidence map›Paper›PMID 37325361›Full record

ArticleFrontiers in pediatrics2023

Identification of serum biomarkers for necrotizing enterocolitis using aptamer-based proteomics.

Stephen Mackay, Lauren C Frazer, Grace K Bailey, Claire M Miller, Qingqing Gong, Olivia N Dewitt, Dhirendra K Singh, Misty Good

Open access · goldAbstract read
In one paragraph

Article in Frontiers in pediatrics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Necrotizing Enterocolitis: What's New and What's Next?International journal of molecular sciences · 2025
    Review
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Stephen MackayDivision of Neonatal-Perinatal Medicine, Department of Pediatrics, The University of North Carolina at Chapel Hill, NC, United States.
Lauren C FrazerDivision of Neonatal-Perinatal Medicine, Department of Pediatrics, The University of North Carolina at Chapel Hill, NC, United States.
Grace K BaileyDivision of Neonatal-Perinatal Medicine, Department of Pediatrics, The University of North Carolina at Chapel Hill, NC, United States.
Claire M MillerDivision of Neonatal-Perinatal Medicine, Department of Pediatrics, The University of North Carolina at Chapel Hill, NC, United States.
Qingqing GongDivision of Newborn Medicine, Department of Pediatrics, Washington University School of Medicine, St. Louis, MO, United States.
Olivia N DewittDivision of Newborn Medicine, Department of Pediatrics, Washington University School of Medicine, St. Louis, MO, United States.
Dhirendra K SinghDivision of Neonatal-Perinatal Medicine, Department of Pediatrics, The University of North Carolina at Chapel Hill, NC, United States.
Misty GoodDivision of Neonatal-Perinatal Medicine, Department of Pediatrics, The University of North Carolina at Chapel Hill, NC, United States.
University of North Carolina at Chapel Hill · USWashington University in St. Louis · US

Funding

Non-invasive analysis of methylated cell free DNA in necrotizing enterocolitisR01DK124614 · NIDDK · WASHINGTON UNIVERSITY · PI GOOD, MISTY L, PETERS, DAVID GERARD · 2021 to 2024
$2.5M
Neonatal gut-on-a-chip platform for high content drug testing and precision medicineR01HD105301 · NICHD · WASHINGTON UNIVERSITY · PI GOOD, MISTY L, MAGNESS, SCOTT T · 2021 to 2024
$2.4M
Modulation of the Intestinal Immune Response in Necrotizing EnterocolitisR01DK118568 · NIDDK · WASHINGTON UNIVERSITY · PI GOOD, MISTY L · 2018 to 2022
$1.8M
NICHD NIH HHS R01 HD105301NIDDK NIH HHS R01 DK118568NIDDK NIH HHS R01 DK124614
6 · The paper itself

Abstract

Introduction: Necrotizing enterocolitis (NEC) is a potentially fatal intestinal disease primarily affecting preterm infants. Early diagnosis of neonates with NEC is crucial to improving outcomes; however, traditional diagnostic tools remain inadequate. Biomarkers represent an opportunity to improve the speed and accuracy of diagnosis, but they are not routinely used in clinical practice. Methods: In this study, we utilized an aptamer-based proteomic discovery assay to identify new serum biomarkers of NEC. We compared levels of serum proteins in neonates with and without NEC and identified ten differentially expressed serum proteins between these groups. Results: We detected two proteins, C-C motif chemokine ligand 16 (CCL16) and immunoglobulin heavy constant alpha 1 and 2 heterodimer (IGHA1 IGHA2), that were significantly increased during NEC and eight that were significantly decreased. Generation of receiver operating characteristic (ROC) curves revealed that alpha-fetoprotein (AUC = 0.926), glucagon (AUC = 0.860), and IGHA1 IGHA2 (AUC = 0.826) were the proteins that best differentiated patients with and without NEC. Discussion: These findings indicate that further investigation into these serum proteins as a biomarker for NEC is warranted. In the future, laboratory tests incorporating these differentially expressed proteins may improve the ability of clinicians to diagnose infants with NEC rapidly and accurately.

Indexed as

aptamerbiomarkernecrotizing enterocolitisprematurityserumSomaScan

Identifiers

PMID37325361
PMCPMC10264655
OpenAlexW4378903802

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.